Format

Send to

Choose Destination
Lancet. 2004 May 1;363(9419):1439-41.

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Author information

1
Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden. Katarina.Leblanc@medhs.ki.se

Abstract

Adult bone-marrow-derived mesenchymal stem cells are immunosuppressive and prolong the rejection of mismatched skin grafts in animals. We transplanted haploidentical mesenchymal stem cells in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver. Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo.

PMID:
15121408
DOI:
10.1016/S0140-6736(04)16104-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center